DMAC · XBRL financial data

DiaMedica Therapeutics financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (DMAC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	8,310	8,765	7,839	13,110	19,057	24,614
General and administrative	4,389	4,881	6,162	8,157	7,624	9,783
Total operating expenses	12,699	13,646	14,001	21,267	26,681	34,397
Operating income (loss)	(12,699)	(13,646)	(14,001)	(21,267)	(26,681)	(34,397)
Interest income	—	—	—	1,951	2,301	1,669
Other income (expense)	229	82	353	1,929	2,267	1,659
Income tax expense (benefit)	27	28	28	43	30	28
Net income (loss)	(12,292)	(13,592)	(13,676)	(19,381)	(24,444)	(32,766)
Earnings per share, basic USD per share	—	(0.65)	(0.52)	(0.60)	(0.60)	(0.70)
Weighted average shares, basic thousands of shares	—	20,773	26,443	32,567	40,405	46,981

Fiscal years (DMAC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	7,409	4,707	4,728	4,543	3,025	15,647
Marketable securities	20,098	40,405	28,774	48,352	41,122	44,243
Marketable securities, non-current	—	—	0	—	0	—
Accounts receivable	340	130	82	369	236	258
Prepaid and other current assets	64	84	251	411	227	481
Total current assets	27,921	45,439	33,835	53,675	44,610	60,629
Property and equipment, net	74	70	136	131	148	145
Right-of-use asset	100	42	424	354	279	197
Total assets	28,095	45,551	34,395	54,160	46,345	61,371
Accounts payable	1,099	509	734	926	940	1,475
Accrued liabilities	864	966	1,365	1,777	4,347	3,545
Total current liabilities	2,028	1,524	2,168	2,786	5,390	5,132
Lease liability, non-current	46	0	4	316	225	124
Accumulated deficit	(68,909)	(82,501)	(96,177)	(115,558)	(140,002)	(172,768)
Total stockholders' equity	26,014	44,024	31,827	51,057	40,718	56,111
Total liabilities and equity	28,095	45,551	34,395	54,160	46,345	61,371
Common shares outstanding (cover page) thousands of shares	18,776	26,443	26,461	37,958	42,856	53,883

Fiscal years (DMAC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(12,292)	(13,592)	(13,676)	(19,381)	(24,444)	(32,766)
Stock-based compensation	1,843	1,558	1,502	1,683	2,085	3,846
Net cash from operating activities	(9,185)	(12,252)	(11,511)	(18,728)	(22,076)	(29,062)
Purchases of property and equipment	47	22	81	24	25	40
Net cash from investing activities	(16,134)	(20,537)	11,538	(18,299)	8,564	(2,192)
Proceeds from issuing common stock	28,805	29,849	0	36,848	11,747	43,282
Net cash from financing activities	28,845	30,087	(6)	36,842	11,994	43,876
Net change in cash	3,526	(2,702)	21	(185)	(1,518)	12,622

The peer list for this company is being put together from its industry's latest filings. Reload the page in a minute to see it.

Not investment advice. Not affiliated with the U.S. SEC.